213 related articles for article (PubMed ID: 17991300)
1. High CD21 expression inhibits internalization of anti-CD19 antibodies and cytotoxicity of an anti-CD19-drug conjugate.
Ingle GS; Chan P; Elliott JM; Chang WS; Koeppen H; Stephan JP; Scales SJ
Br J Haematol; 2008 Jan; 140(1):46-58. PubMed ID: 17991300
[TBL] [Abstract][Full Text] [Related]
2. Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas.
Gerber HP; Kung-Sutherland M; Stone I; Morris-Tilden C; Miyamoto J; McCormick R; Alley SC; Okeley N; Hayes B; Hernandez-Ilizaliturri FJ; McDonagh CF; Carter PJ; Benjamin D; Grewal IS
Blood; 2009 Apr; 113(18):4352-61. PubMed ID: 19147785
[TBL] [Abstract][Full Text] [Related]
3. SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies.
Blanc V; Bousseau A; Caron A; Carrez C; Lutz RJ; Lambert JM
Clin Cancer Res; 2011 Oct; 17(20):6448-58. PubMed ID: 22003072
[TBL] [Abstract][Full Text] [Related]
4. Development of novel anti-CD19 antibody-drug conjugates for B-cell lymphoma treatment.
Li Z; Wang M; Yao X; Li H; Li S; Liu L; Yu D; Li X; Fang J; Huang C
Int Immunopharmacol; 2018 Sep; 62():299-308. PubMed ID: 30048860
[TBL] [Abstract][Full Text] [Related]
5. Cross-linking CD21/CD35 or CD19 increases both B7-1 and B7-2 expression on murine splenic B cells.
Kozono Y; Abe R; Kozono H; Kelly RG; Azuma T; Holers VM
J Immunol; 1998 Feb; 160(4):1565-72. PubMed ID: 9469411
[TBL] [Abstract][Full Text] [Related]
6. Complement component C3d-antigen complexes can either augment or inhibit B lymphocyte activation and humoral immunity in mice depending on the degree of CD21/CD19 complex engagement.
Lee Y; Haas KM; Gor DO; Ding X; Karp DR; Greenspan NS; Poe JC; Tedder TF
J Immunol; 2005 Dec; 175(12):8011-23. PubMed ID: 16339538
[TBL] [Abstract][Full Text] [Related]
7. Role of complement-binding CD21/CD19/CD81 in enhancing human B cell protection from Fas-mediated apoptosis.
Mongini PK; Jackson AE; Tolani S; Fattah RJ; Inman JK
J Immunol; 2003 Nov; 171(10):5244-54. PubMed ID: 14607925
[TBL] [Abstract][Full Text] [Related]
8. Role of CD21 antigen in diffuse large B-cell lymphoma and its clinical significance.
Otsuka M; Yakushijin Y; Hamada M; Hato T; Yasukawa M; Fujita S
Br J Haematol; 2004 Nov; 127(4):416-24. PubMed ID: 15521918
[TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr viruses that express a CD21 antibody provide evidence that gp350's functions extend beyond B-cell surface binding.
Busse C; Feederle R; Schnölzer M; Behrends U; Mautner J; Delecluse HJ
J Virol; 2010 Jan; 84(2):1139-47. PubMed ID: 19889766
[TBL] [Abstract][Full Text] [Related]
10. Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.
Mihara K; Yanagihara K; Takigahira M; Kitanaka A; Imai C; Bhattacharyya J; Kubo T; Takei Y; Yasunaga S; Takihara Y; Kimura A
Br J Haematol; 2010 Oct; 151(1):37-46. PubMed ID: 20678160
[TBL] [Abstract][Full Text] [Related]
11. A novel antibody-drug conjugate anti-CD19(Fab)-LDM in the treatment of B-cell non-Hodgkin lymphoma xenografts with enhanced anticancer activity.
Jiang L; Yang M; Zhang X; Bao S; Ma L; Fan D; Zhou Y; Xiong D; Zhen Y
J Drug Target; 2016; 24(1):47-57. PubMed ID: 26204323
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibodies to lymphocyte surface antigens for cetacean homologues to CD2, CD19 and CD21.
De Guise S; Erickson K; Blanchard M; DiMolfetto L; Lepper HD; Wang J; Stott JL; Ferrick DA
Vet Immunol Immunopathol; 2002 Jan; 84(3-4):209-21. PubMed ID: 11777535
[TBL] [Abstract][Full Text] [Related]
13. A role for CD21/CD35 and CD19 in responses to acute septic peritonitis: a potential mechanism for mast cell activation.
Gommerman JL; Oh DY; Zhou X; Tedder TF; Maurer M; Galli SJ; Carroll MC
J Immunol; 2000 Dec; 165(12):6915-21. PubMed ID: 11120817
[TBL] [Abstract][Full Text] [Related]
14. A superantigen-antibody fusion protein for T-cell immunotherapy of human B-lineage malignancies.
Gidlöf C; Dohlsten M; Lando P; Kalland T; Sundström C; Tötterman TH
Blood; 1997 Mar; 89(6):2089-97. PubMed ID: 9058731
[TBL] [Abstract][Full Text] [Related]
15. Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma.
Polson AG; Williams M; Gray AM; Fuji RN; Poon KA; McBride J; Raab H; Januario T; Go M; Lau J; Yu SF; Du C; Fuh F; Tan C; Wu Y; Liang WC; Prabhu S; Stephan JP; Hongo JA; Dere RC; Deng R; Cullen M; de Tute R; Bennett F; Rawstron A; Jack A; Ebens A
Leukemia; 2010 Sep; 24(9):1566-73. PubMed ID: 20596033
[TBL] [Abstract][Full Text] [Related]
16. Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab.
Rossi EA; Goldenberg DM; Michel R; Rossi DL; Wallace DJ; Chang CH
Blood; 2013 Oct; 122(17):3020-9. PubMed ID: 23821660
[TBL] [Abstract][Full Text] [Related]
17. CD21 and CD19 deficiency: Two defects in the same complex leading to different disease modalities.
Wentink MW; Lambeck AJ; van Zelm MC; Simons E; van Dongen JJ; IJspeert H; Schölvinck EH; van der Burg M
Clin Immunol; 2015 Dec; 161(2):120-7. PubMed ID: 26325596
[TBL] [Abstract][Full Text] [Related]
18. CD19 can regulate B lymphocyte signal transduction independent of complement activation.
Hasegawa M; Fujimoto M; Poe JC; Steeber DA; Tedder TF
J Immunol; 2001 Sep; 167(6):3190-200. PubMed ID: 11544305
[TBL] [Abstract][Full Text] [Related]
19. A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies.
Deckert J; Park PU; Chicklas S; Yi Y; Li M; Lai KC; Mayo MF; Carrigan CN; Erickson HK; Pinkas J; Lutz RJ; Chittenden T; Lambert JM
Blood; 2013 Nov; 122(20):3500-10. PubMed ID: 24002446
[TBL] [Abstract][Full Text] [Related]
20. The increased expression of CD21 on AchR specified B cells in patients with myasthenia gravis.
Yin W; Allman W; Ouyang S; Li Y; Li J; Christadoss P; Yang H
J Neuroimmunol; 2013 Mar; 256(1-2):49-54. PubMed ID: 23266128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
